Endologix (NASDAQ:ELGX) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.
Several other equities research analysts have also issued reports on ELGX. Stifel Nicolaus increased their price objective on shares of Endologix from $4.50 to $5.00 and gave the stock a “hold” rating in a research report on Monday, May 21st. Zacks Investment Research raised shares of Endologix from a “sell” rating to a “hold” rating in a research report on Monday, May 7th. Oppenheimer set a $5.00 price objective on shares of Endologix and gave the stock a “hold” rating in a research report on Thursday, May 3rd. Finally, ValuEngine raised shares of Endologix from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. Endologix currently has a consensus rating of “Hold” and an average price target of $4.95.
Shares of Endologix opened at $5.65 on Thursday, Marketbeat.com reports. Endologix has a one year low of $3.75 and a one year high of $6.50. The company has a quick ratio of 1.37, a current ratio of 2.13 and a debt-to-equity ratio of 3.58. The company has a market cap of $448.61 million, a P/E ratio of -11.81 and a beta of 0.32.
Endologix (NASDAQ:ELGX) last issued its quarterly earnings results on Wednesday, May 2nd. The medical instruments supplier reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.03. Endologix had a negative net margin of 35.86% and a negative return on equity of 47.01%. The firm had revenue of $42.28 million during the quarter, compared to analyst estimates of $41.14 million. During the same quarter in the prior year, the business posted ($0.18) earnings per share. Endologix’s revenue for the quarter was down .8% compared to the same quarter last year. research analysts anticipate that Endologix will post -0.7 EPS for the current year.
Hedge funds have recently made changes to their positions in the company. Lake Street Advisors Group LLC purchased a new position in shares of Endologix in the fourth quarter valued at $120,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Endologix in the fourth quarter valued at $139,000. Teacher Retirement System of Texas purchased a new position in shares of Endologix in the fourth quarter valued at $144,000. MetLife Investment Advisors LLC purchased a new position in shares of Endologix in the fourth quarter valued at $236,000. Finally, Millrace Asset Group Inc. purchased a new position in shares of Endologix in the fourth quarter valued at $669,000. Institutional investors and hedge funds own 99.15% of the company’s stock.
Endologix Company Profile
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.